GI
BMRN icon

GAMCO Investors’s BioMarin Pharmaceuticals BMRN Stock Holding History

GAMCO Investors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$744K Sell
13,000
-150
-1% -$8.22K 0.01% 658
2026
Q1 		$743K Hold
13,150
– – 0.01% 677
2025
Q4 		$782K Hold
13,150
– – 0.01% 702
2025
Q3 		$712K Buy
13,150
+5,150
+64% +$295K 0.01% 725
2025
Q2 		$440K Sell
8,000
-290
-3% -$17.1K ﹤0.01% 847
2025
Q1 		$586K Sell
8,290
-1,750
-17% -$118K 0.01% 650
2024
Q4 		$660K Buy
10,040
+3,475
+53% +$233K 0.01% 651
2024
Q3 		$461K Buy
6,565
+1,250
+24% +$104K ﹤0.01% 706
2024
Q2 		$438K Buy
+5,315
New +$442K ﹤0.01% 710
2024
Q1 		– Sell
-2,483
Closed -$239K – 861
2023
Q4 		$239K Sell
2,483
-231
-9% -$20.4K ﹤0.01% 781
2023
Q3 		$240K Sell
2,714
-470
-15% -$41.8K ﹤0.01% 779
2023
Q2 		$276K Sell
3,184
-360
-10% -$33.9K ﹤0.01% 768
2023
Q1 		$345K Buy
3,544
+290
+9% +$30.1K ﹤0.01% 739
2022
Q4 		$337K Sell
3,254
-243
-7% -$22.8K ﹤0.01% 748
2022
Q3 		$296K Buy
3,497
+95
+3% +$8.46K ﹤0.01% 755
2022
Q2 		$282K Sell
3,402
-660
-16% -$52.5K ﹤0.01% 783
2022
Q1 		$313K Sell
4,062
-703
-15% -$58.8K ﹤0.01% 802
2021
Q4 		$421K Sell
4,765
-5,653
-54% -$466K ﹤0.01% 766
2021
Q3 		$805K Sell
10,418
-386
-4% -$30.5K 0.01% 666
2021
Q2 		$901K Buy
10,804
+30
+0.3% +$2.38K 0.01% 661
2021
Q1 		$814K Buy
10,774
+6,504
+152% +$531K 0.01% 661
2020
Q4 		$374K Buy
+4,270
New +$339K ﹤0.01% 769
2019
Q2 		– Sell
-2,300
Closed -$204K – 930
2019
Q1 		$204K Buy
+2,300
New +$213K ﹤0.01% 810
2018
Q4 		– Sell
-2,300
Closed -$223K – 800
2018
Q3 		$223K Hold
2,300
– – ﹤0.01% 792
2018
Q2 		$217K Sell
2,300
-300
-12% -$26.3K ﹤0.01% 809
2018
Q1 		$211K Hold
2,600
– – ﹤0.01% 792
2017
Q4 		$232K Buy
+2,600
New +$226K ﹤0.01% 785

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

GAMCO Investors's BMRN Position: Q2 2026 in Review

GAMCO Investors reduced its BioMarin Pharmaceuticals (BMRN) stake by 1.1% in Q2 2026, selling an estimated $8.22K and leaving 13,000 shares worth $744K. The position accounts for 0.01% of the portfolio, ranked #658.

GAMCO Investors first reported a position in BMRN in Q4 2017 and has held it in 27 quarters since. The position peaked at $901K in Q2 2021. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • GAMCO Investors held 13,000 shares of BioMarin Pharmaceuticals worth $744K as of Q2 2026.
  • GAMCO Investors sold 150 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $8.22K.
  • BioMarin Pharmaceuticals made up 0.01% of GAMCO Investors's portfolio in Q2 2026, its #658 holding.
  • GAMCO Investors first reported a position in BioMarin Pharmaceuticals in Q4 2017 and has held it in 27 quarters since.
  • GAMCO Investors's BioMarin Pharmaceuticals position peaked at $901K in Q2 2021.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on GAMCO Investors's 13F filing for Q2 2026, filed 12 Aug 2026.